Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 6/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | DHODH | Q02127 | 1/20 | 0.31 |
| ▸ | F10 | P00742 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16676367 | 0.86 | GAA (0.44) | GAAKMT2ADDR1MAPTTP53 | |
| SCHEMBL16529560 | 0.82 | DDR1 (0.39) | GAAKMT2ADDR1MAPTEGFR | |
| SCHEMBL16676499 | 0.78 | GAA (0.38) | GAAKMT2ADDR1MAPTEGFR | |
| SCHEMBL16676266 | 0.76 | GAA (0.43) | GAAKMT2AMAPTEGFRF10 | |
| SCHEMBL16676307 | 0.72 | L3MBTL1 (0.44) | GAAKMT2AMAPTTP53F10 | |
| SCHEMBL16676293 | 0.71 | DDR1 (0.38) | KMT2ADDR1 | |
| SCHEMBL16676536 | 0.69 | DDR1 (0.38) | GAAKMT2ADDR1MAPTEGFR | |
| SCHEMBL16529626 | 0.68 | DDR1 (0.54) | DDR1 | |
| SCHEMBL16529561 | 0.67 | DDR1 (0.36) | KMT2ADDR1MAPTTP53F10 | |
| SCHEMBL16676471 | 0.67 | SMN1; SMN2 (0.36) | KMT2AMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005739-B2 | Quinazolinone and isoquinolinone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2018-06-26 | — | — | US | disclosed |
| US-10005739-B2 | Quinazolinone and isoquinolinone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2018-06-26 | — | — | US | disclosed |
| US-20160272595-A1 | QUINAZOLINONE AND ISOQUINOLINONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-09-22 | — | — | US | disclosed |
| US-20160272595-A1 | QUINAZOLINONE AND ISOQUINOLINONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-09-22 | — | — | US | disclosed |
| EP-3061749-A1 | QUINAZOLINONE AND ISOQUINOLINONE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2016-08-31 | — | — | EP | disclosed |
| EP-3061749-A1 | QUINAZOLINONE AND ISOQUINOLINONE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2016-08-31 | — | — | EP | disclosed |
| WO-2015060373-A1 | QUINAZOLINONE AND ISOQUINOLINONE DERIVATIVE | 中外製薬株式会社 | 2015-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272595-A1 | QUINAZOLINONE AND ISOQUINOLINONE DERIVATIVE | NQO2, SDHA, CYP3A5 | GAA 1500/4885KMT2A 2733/4885DDR1 4404/4885 |
| US-10005739-B2 | Quinazolinone and isoquinolinone derivative | NQO2, SDHA, CYP3A5 | GAA 1500/4885KMT2A 2733/4885DDR1 4404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.